EP1526910A2 - Materiau filtrant pour toxines, bacteries, virus et autres substances physiologiques nocives - Google Patents

Materiau filtrant pour toxines, bacteries, virus et autres substances physiologiques nocives

Info

Publication number
EP1526910A2
EP1526910A2 EP03737999A EP03737999A EP1526910A2 EP 1526910 A2 EP1526910 A2 EP 1526910A2 EP 03737999 A EP03737999 A EP 03737999A EP 03737999 A EP03737999 A EP 03737999A EP 1526910 A2 EP1526910 A2 EP 1526910A2
Authority
EP
European Patent Office
Prior art keywords
filter material
material according
aryl
alkyl
acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03737999A
Other languages
German (de)
English (en)
Inventor
Hans-Uwe Wolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PLT Patent and License Trading Ltd
Original Assignee
Dormann Jorg Martin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dormann Jorg Martin filed Critical Dormann Jorg Martin
Publication of EP1526910A2 publication Critical patent/EP1526910A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
    • B01J20/3204—Inorganic carriers, supports or substrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
    • B01J20/3206—Organic carriers, supports or substrates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/20—Pathogenic agents
    • A61M2202/203—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/20—Pathogenic agents
    • A61M2202/206—Viruses

Definitions

  • the invention relates to a filter material for toxins, bacteria, viruses and other physiological pollutants, which can be used in hemoperfusion to rid the blood of such pollutants.
  • the filter material is based on compounds from the class of calixarenes and reosrcinarene.
  • Hemoperfusion is one of the (most effective measures for extracorporeal elimination of toxins and pollutants.
  • hemoperfusion In contrast to hemodialysis, hemoperfusion is able to eliminate lipophilic substances that are not suitable for dialysis from the blood. However, hemoperfusion is usually superior to substances capable of dialysis. An important side effect, which has not yet been eliminated, is the undesired adsorption of throinocytes, which can be in a range up to about 40%.
  • a filter material which consists of a compound of the general formula I
  • R H, alkyl, aryl, alkyloxy, aryloxy, amine, amide, carboxylic acids and sulfonic acids with • 1 to 12 carbon atoms, amino acids, sugar or crown ether,
  • Ri H, alkyl, aryl, alkyloxy, aryloxy, amine, amide, carboxylic acids and sulfonic acids with 1 to 12 carbon atoms, sulfonamides, amino acids, sugars, crown ethers, cyclodextrins, purine bases or pyridine bases,
  • R H, alkyl, aryl, alkyloxy, aryloxy, amine, amide, carboxylic acids and sulfonic acids with 1 to 12 carbon atoms or amino acids
  • Ri H, alkyl, aryl, alkyloxy, aryloxy, amine, amide, carboxylic acids and sulfonic acids with 1 to 12 carbon atoms, sulfona ide, amino acids, sugar, crown ethers, cyclodextrins, purine bases or pyrimidine bases,
  • R 2 * alkyl or aryl
  • R 3 and 4 0, where R 3 and R are bridged together via methylene, ethylene or quinoxaline
  • the designated aromatic systems can be any heteroatoms, e.g. B. 0, S, N, have.
  • the peculiarity of the solution according to the invention is based on the fact that the macromolecules used from the group of the calixarenes and resorcinarenes are easily accessible synthetically and can be modified universally. So you can open them up. Optimize various requirements regarding the substance classes of the toxins to be eliminated. It is particularly interesting in view of the fact that a large number of substances have hitherto been insufficiently eliminated, for example B. Paraquat and Diquat.
  • any matrices known from the prior art can be used as the carrier.
  • the filter material it is also possible for the filter material to contain or consist of biomatrixes such as cotton or cellulose.
  • Micelle formers or compounds from the group cyclodextrins are preferably contained as additives.
  • cyclodextrins are significantly more polar and hydrophilic than calixarenes or resorcinarenes, which means that. certain applications a higher hydrophilicity of the filter material than can be realized.
  • the calixarenes or resorcinarenes of the general formulas I and II must be modified depending on the pollutant to be eliminated.
  • the modification takes place from the point of view of optimizing the interaction between the filter material and the relevant target molecule, ie. H. the pollutant.
  • hydrophilic groups in the compounds are necessary to ensure water solubility.
  • modification options of the filter material are to be mentioned here only by way of example in order to implement special applications. This includes, on the one hand, modifying the filter material with sugars that can interact with bacteria, making them accessible for hemoperfusion, so that they can be filtered out of physiological fluids. By modifying the filter material with amino acids, an interaction with viruses can also be made possible, so that these can also be separated using hemoperfusion.
  • the filter material provides that the compound of the general formulas I and II are modified with antibodies. This enables the rapid elimination of antigens due to antigen-antibody interactions. With aggressive viruses in particular, there is the possibility of removing antigens from the organism until the immune system has stabilized.
  • the filter material is based on the fact that the compounds of the general formulas I and II have a high temperature resistance, which can be exploited in such a way that recyclable filter materials can be provided.
  • Appropriate thermal treatment thermally decomposes the pollutants eliminated from the blood, while the compounds of the general formulas I and II contained in the filter material remain stable. Such thermal treatments are preferably carried out above 300 ° C. Compared to the filter materials known from the prior art, the inventive materials thus have a significantly higher thermal stability.
  • the filter material is preferably integrated into common filter devices. This includes, for example, cartridges, frits, disks or membranes.
  • the filter material according to the invention is preferably used for the hemoperfusion of physiological liquids.
  • Blood, plasma or urine are only examples of physiological fluids.
  • the subject according to the invention is intended to be explained in more detail with reference to the following figure and the examples, without restricting it to the exemplary embodiments mentioned.
  • 1 shows a schematic structural model of the tetrasulfonic acid calix [4] arene-paraquat complex.
  • a paraquat molecule shows the incorporation of a paraquat molecule into a tetrasulfonic acid calix [4] arene system.
  • the paraquat is bound to the filter material via different interactions. This includes a cation-OH interaction 1, a cation- ⁇ interaction 2, a CH- ⁇ interaction 3 and a ⁇ - ⁇ interaction 4.
  • the complex formation constant is very large and can be in the range 10 5 are up to 10 ⁇ . This means that paraquat is stored irreversibly and can thus be permanently removed from the bloodstream, for example by hemoperfusion.
  • the sulfuric acid is added all at once to the calix [4] arene in a 100 ml three-necked flask with gas inlet and outlet devices.
  • the apparatus is flushed with argon and the reaction mixture is stirred at 80 ° C. for about 4 hours.
  • the course of the reaction is followed by taking a sample and checking the solubility in water. If the mixture is soluble in water without a residue, the reaction is stopped.
  • the crude product is filtered off with a glass frit (4 A), dissolved in methanol (in order to remove remaining sulfuric acid) and precipitated with ethyl acetate.
  • the white precipitate is dried in an oil pump vacuum-
  • Paraquat is a very effective contact herbicide and as such has been widely used for many decades.
  • the toxic effect on plants is based on the inhibition of photosynthesis by the formation of radical intermediates which prevent the NADP reduction. This hinders the transmission of energy. It is 'non-toxic to rapidly oxygen, reduced well waser- soluble compounds, whereby it is a good way to carry out the control of weeds in time selectively and relatively umweitschonend' in the field in the presence of light and.
  • Paraquat has repeatedly resulted in numerous acute and chronic poisonings in humans when used in agriculture or when attempting suicide. Symptoms such as eye damage, kidney and liver damage, gastritis and lung diseases occur until death from suffocation. Therapeutic measures are limited because there is no specific antidote. Adsorption on activated carbon or carbon filters is weak, which is why stronger interactions with adsorbents are sought.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un matériau filtrant pour toxines, bactéries, virus et autres substances physiologiques nocives, qui peut être utilisé lors d'une hémoperfusion pour extraire des substances nocives de ce type de fluides physiologiques. Ce matériau filtrant est basé sur des composés de la classe des calixarène et résorcinarène. Lesdits fluides physiologiques sont par exemple du sang, du plasma ou de l'urine.
EP03737999A 2002-06-12 2003-06-06 Materiau filtrant pour toxines, bacteries, virus et autres substances physiologiques nocives Withdrawn EP1526910A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10226099A DE10226099A1 (de) 2002-06-12 2002-06-12 Filtermaterial für Toxine, Bakterien, Viren und andere physiologische Schadstoffe
DE10226099 2002-06-12
PCT/EP2003/005957 WO2003105990A2 (fr) 2002-06-12 2003-06-06 Materiau filtrant pour toxines, bacteries, virus et autres substances physiologiques nocives

Publications (1)

Publication Number Publication Date
EP1526910A2 true EP1526910A2 (fr) 2005-05-04

Family

ID=29718988

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03737999A Withdrawn EP1526910A2 (fr) 2002-06-12 2003-06-06 Materiau filtrant pour toxines, bacteries, virus et autres substances physiologiques nocives

Country Status (4)

Country Link
EP (1) EP1526910A2 (fr)
AU (1) AU2003245917A1 (fr)
DE (1) DE10226099A1 (fr)
WO (1) WO2003105990A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8556085B2 (en) 2010-11-08 2013-10-15 Stuart Bogle Anti-viral device

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989008092A1 (fr) * 1988-02-29 1989-09-08 The Flinders University Of South Australia Separation de composes organiques contenus dans des fluides
US5312837A (en) * 1991-01-29 1994-05-17 Genelabs Technologies, Inc. Method of treating viral infections with aryl macrocyclic compounds
AU4803393A (en) * 1992-08-06 1994-03-03 Genelabs Technologies, Inc. Inhibition and treatment of infection by enveloped virus with calix(n) arene compounds
AU1545395A (en) * 1994-01-24 1995-08-08 Stephen J. Harris Calixarene-based compounds having antibacterial, antifungal, anticancer-hiv activity
EP0883432A1 (fr) * 1996-02-28 1998-12-16 Transdiffusia S.A. Procede de recuperation de composes volatils de faible masse moleculaire
JPH11209740A (ja) * 1998-01-19 1999-08-03 Kurita Water Ind Ltd ハロゲン化エチレン化合物の分離剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03105990A2 *

Also Published As

Publication number Publication date
AU2003245917A8 (en) 2003-12-31
WO2003105990A2 (fr) 2003-12-24
AU2003245917A1 (en) 2003-12-31
DE10226099A1 (de) 2004-01-08
WO2003105990A3 (fr) 2004-04-01

Similar Documents

Publication Publication Date Title
EP0533727B1 (fr) MATERIAU ADSORBANT D'ELIMINATION SELECTIVE DE LDL ET/OU vLDL
DE3115608C2 (de) Vorrichtung für die Adsorption von Blutproteinen
Hostettmann Saponins with molluscicidal activity from Hedera helixL
DE69605395T2 (de) Vorrichtung zum extrakoporealen Entfernen von Toxinen, insbesondere Zytokinen
DE69424339T2 (de) Positiv geladene Membran aus Polyvinylidenfluorid
DE2746942A1 (de) Neue psoralenderivate
DE69834651T2 (de) Filtermaterial zur entfernung von weissen blutkörperchen
DE4331358A1 (de) Verfahren zur quantitativen selektiven Entfernung oder präparativen Gewinnung von Tumor-Nekrose-Faktor (TNF) oder/und Lipopolysacchariden (LPS) aus wäßrigen Flüssigkeiten
DE60009723T2 (de) Verfahren zur abtrennung von lactonhaltigen verbindungen mit hohem molekulargewicht
DE10045434A1 (de) Adsorbens mit unterschiedlich modifizierten Oberflächenbereichen, Verfahren zu dessen Herstellung und Verwendung davon
DE69218477T2 (de) Medizinisches Material, Verfahren zu seiner Herstellung und medizinisches Gerät
EP0548794A2 (fr) Dérivés de polyaspartamide adsorbant les acides biliaires, dérivés de polyaspartamide chargés d'acides biliaires et leur procédé de préparation et leur utilisation comme médicament
DE10011481A1 (de) Adsorbens zum Absenken der Konzentration von Fibrinogen und/oder Fibrin, Verwendung des Adsorbens zur Herstellung eines Adsorbers und Adsorber mit dem Adsorbens
DE69330458T2 (de) Verfahren zur gewinnung eines hochreinen factor viii/von willebrand faktor komplexes durch anionenaustauschchromatographie
DE3926539A1 (de) Verwendung von tentakel-kationenaustauschern zur selektiven eliminierung von low-density-lipoproteinen (ldl), fibrinogen und/oder harnstoff aus fluessigkeiten
EP1132129A1 (fr) Méthode de préparation d'un adsorbant pour diminuer la concentration de fibrinogène et/ou de fibrine, adsorbant et son utilisation dans la fabrication d'un adsorbeur
EP1526910A2 (fr) Materiau filtrant pour toxines, bacteries, virus et autres substances physiologiques nocives
DE69219384T2 (de) Packungen mit über Spacer an Träger gebundenem Protein
EP1104674A1 (fr) Colorants o-o'-dihydroxy azoiques dans des médicaments ayant une activité TPO-agoniste ou synergétique
DE60131710T2 (de) Verfahren zur Adsorption und Entfernung, und Verwendung eines Adsorbers für endogene Cannabinoide
DE10147463A1 (de) Verfahren zur Aufreinigung von Vollblut
CN106928309B (zh) 一种螺旋甾碱烷型糖苷生物碱及其制备方法与用途
DE69525297T2 (de) Adsorbens fuer ketoamine enthaltende proteine
DE3715447C2 (de) Verfahren zur Herstellung einer Mischung von O-(beta-Hydroxyethyl)-diosminen
CN106939031B (zh) 一种螺旋甾碱烷型糖苷生物碱及其制备方法与用途

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050112

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PLT PATENTS & LICENCE TRADING LTD.

17Q First examination report despatched

Effective date: 20080618

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081230